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Abstract
Background:  Viral hepatitis is highly endemic in Israel, with the hepatitis A virus (HAV)
responsible for most cases. Improved socioeconomic factors, as well as the universal vaccination
of infants (introduced in 1999) has resulted in a decline in infection rates in Israel. This study
examines the benefits of routine testing for anti-HAV IgG in high-risk population.
Methods: A retrospective examination of the files of teenage and adult patients (aged 16–99 years;
mean 33.9) in two primary care clinics found 1,017 patients who had been tested for anti-HAV IgG
antibodies for either general healthcare screening or ongoing follow-up for chronic illness.
Seropositive patients were then asked regarding recall of past hepatitis (i.e. jaundice, regardless of
viral etiology); post-exposure prophylaxis with immune serum immunoglobulin (ISG); and active
immunization with inactivated virus. Seronegative patients were subsequently sent for active
immunization.
Results:  Of the1,017 patient records studied (503 male, 514 female), a total of 692 were
seropositive (354 males, 338 females; P = 0.113). Seropositivity rates increased with age (p <
0.005), and were highest among those born in Middle Eastern countries other than Israel (91.3%)
and lowest among immigrants from South America (44.1%; P < 0.005). 456 of the seropositive
patients were interviewed, of whom only 91 recalled past illness while 103 remembered receiving
post-exposure prophylaxis (ISG) and 8 active vaccination. Those who were unaware of past
infection were more likely to have been vaccinated with ISG than those who were aware (26.3%
vs. 7.7%; p < 0.005).
Conclusion: The relatively high prevalence rate of anti-HAV seropositivity in our study may me
due to the fact that the study was conducted in a primary care clinic or that it took place in
Jerusalem, a relatively poor and densely populated Israeli city. Most of the seropostive patients had
no recollection of prior infection, which can be explained by the fact that most hepatitis A
infections occur during childhood and are asymptomatic. Routine testing for anti-HAV IgG in
societies endemic for HAV would help prevent seropositive patients from receiving either post-
exposure or preventive immunization and target seronegative patients for preventive vaccination.
Background
For years Israel has been considered to be endemic for
viral hepatitis, with an incidence of reported cases five to
ten times that observed in the United States [1]. Most
cases of viral hepatitis in Israel are caused by the hepatitis
A virus (HAV), and in the 1970's the Israeli Ministry of
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Health instituted a wide-scale program of post-exposure
prophylaxis with immune serum globulin (ISG). In 1999
universal immunization with inactivated virus (Havrix;
Smith Klein Beecham) was instituted for infants, the first
dose being given at 18 months and the second at 24 – 30
months of age [2]. The Israel Defense Forces (IDF) have
instituted vaccination programs as well, first with ISG
and, more recently, with the inactivated virus [3].
Vaccination programs, as well socioeconomic changes,
have led to a significant reduction in the prevalence of
HAV infection in Israel today [4,5]. In the United States,
the U.S. Advisory Committee on Immunization Practices
has given clear recommendations for vaccinating commu-
nities with high rates of infection (>20 cases per 100,000)
or populations at risk for liver failure [6]. However, no
guidelines exist for routine testing for HAV serology prior
to vaccination, a policy which could potentially prevent
unnecessary immunizations (both active and passive) in
seropositive patients as well as target those who are seron-
egative for active immunization. The following study
examined the current prevalence of anti-HAV serology in
a selected Israeli population (patients presenting to a pri-
mary care clinic), evaluating the benefits of routine testing
for populations at risk.
Methods
The records of teenage and adult patients (aged 16–99
years; mean 33.9) from two primary care clinics in Jerusa-
lem, Israel, were retrospectively searched for anti-HAV IgG
serology. The clinics are affiliated with the Maccabi Health
Care Services, one of four government-funded services
available to all Israeli citizens. Patients had undergone
general blood tests for a number of reasons, either for fol-
low-up of existing illness (none of which were hepatic-
related) or for routine health screening, including anti-
HAV IgG serology. A total of 1,017 patient files were
found which contained serological results of anti-HAV
antibodies from blood analyzed in the health fund's cen-
tral lab, which used a microparticle enzymatic assay
(MEA; AxSYM System, Abbott Diagnostics). Patients who
tested seropositive for HAV were then contacted (either in
person or by phone) and asked regarding the following:
demographic data (country of birth); whether or not they
remembered being sick with hepatitis (i.e. clinical jaun-
dice, with or without known serological evidence of active
HAV infection), and when; and whether or not they had
been immunized, either passively (ISG) or actively (inac-
tivated virus), and when. Recall of past infection was
based on patient reporting alone and not through review
of medical or laboratory records. Data was compiled and
analyzed using the Microsoft Excel program.
Results
Prevalence of HAV seropositivity
As mentioned above, a total of 1,017 patient records (503
males and 514 females) were found to contain results of
anti-HAV antibodies (from March 1998 to September
2003). The mean age of the study group was 33.9 years;
37.8 among males (range: 16–99) and 31.2 among
females (range: 16–87). Among the recorded results, 692
(68.0%) were seropositive – 354 of the male patients
(70.4%) and 338 of the female patients (65.8%; p =
0.113). The rates of seropositivity increased with age (see
Figure 1; p < 0.005), and remained constant throughout
the years of the study (p = 0.451).
Patients who were born in Middle Eastern countries other
than Israel had the highest seropositive rate (91.3%),
while those born in South America the lowest (44.1%; p <
0.005. See Figure 2). Immigrants from the Eastern Bloc
countries (former Soviet Bloc and Eastern Europe) had a
significantly higher prevalence of anti-HAV antibodies
than native Israelis (70.3% vs. 58.7%; p = 0.016).
Recall of past infection and immunization
Of the 658 patients with anti-HAV antibodies, 456 were
interviewed and asked regarding past infection and vacci-
nations (231 males and 225 females). Only 91 had any
recollection of prior illness (20.0%) – 51 of the males
interviewed (22.1%) and 40 of the females (17.8%; p =
0.249), all of them at least 5 years prior to undergoing the
serological testing. A total of 103 respondents remem-
bered receiving post-exposure prophylaxis (passive
immunization) with ISG. Those who were unaware of
past infection were more likely to have been vaccinated
Prevalence of positive HAV serology according to age (%) Figure 1
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with ISG than those who were aware (26.3% vs. 7.7%; p <
0.005). The reasons given for receiving ISG are listed in
Table 1. Eight patients (2 male, 6 female) reported receiv-
ing the inactivated virus vaccine, of which none were
aware of prior illness.
Discussion
Although Israel is considered endemic for HAV infection,
the prevalence of anti -HAV antibodies in our study pop-
ulation (68%) is much higher than that found in other
studies, especially among the under-20 age group
(62.8%). In a 1996 study of teenagers undergoing pre-
draft evaluation, only 38.4% were seropositive [5], while
serum samples from the Israeli Center for Disease Con-
trol's national serum bank in 1989 were seropositive for
HAV in only 27% of 16 year-olds [4]. The relatively high
prevalence of anti-HAV antibodies found in our study
may be due to the fact that the study was conducted in a
primary care clinic, with higher morbidity rates than the
general population, though not liver-related. Another fac-
tor is the fact that both clinics are located in Jerusalem,
one of Israel's poorest and most densely populated cities.
Many of the patients were ultra-orthodox Yeshiva students
who are at greater risk for HAV infection [7] and are not
drafted into the IDF. At the same time, the higher rate of
seropositivity among immigrants from Eastern bloc coun-
tries is consistent with the findings of an earlier study of
this population [8], though another study of pre-draft
teenagers did not find a significant difference between
these immigrants and native Israelis [9].
Most of the seropositive patients in our study (80%) had
no prior recollection of HAV infection. For 70% of chil-
dren under the age of 6 (in communities with high rates
of hepatitis A, 30–40% of children acquire infection
before the age of 5 6) HAV infection is a self-limited, sub-
clinical disease [10]. Among older children and adults,
infection is usually symptomatic, with jaundice occurring
in more than 70% of patients [11]. Signs and symptoms
usually last less than 2 months, although 10–15% of
symptomatic persons have prolonged or relapsing disease
lasting up to 6 months [12]. Case fatality rates also
increase with age, rising from 1.5/1000 among children
less than 5 years old to 27/1000 after age 50 [13], making
vaccination of unimmunized adults that much more
important.
Both ISG and inactivated HAV vaccines are safe, though
not without potential side effects both locally and system-
ically [6,14]. Aside from having to undergo two injections
within a span of 6 months to a year, adult patients in
Israel are required to purchase the active vaccine them-
selves. Seropositive patients in our study who were
unaware of their immune status were more likely (by a
factor of 3.4) to have unnecessarily received ISG (unnec-
essarily since they most likely have lifetime immunity)
than those who were aware of past infection. This is prob-
ably an underestimate, since both post-exposure and pre-
induction vaccinations have been implemented in Israel
for nearly thirty years, and it is likely that many have for-
gotten receiving immunizations in the distant past. For
the eight patients who received the inactivated virus with-
out prior serological testing, it is possible (and even prob-
able) that they too were immunized unnecessarily. Now it
is too late to know whether their current seropositive sta-
tus is a result of past occult infection (with lifetime immu-
Prevalence of positive HAV serology according to country of  birth(%) Figure 2
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nity) or active immunization. These patients will now
have to receive periodic booster vaccinations, which may
have been unnecessary if prior immune status had been
checked. Testing for HAV serology prior to active immuni-
zation has been shown to be both cost-effective and eco-
nomically valid for Israeli travelers, assuming a cost of
$130 for vaccination (which is subsidized but not free for
the patient) and $30 for the IgG test (free for the patient)
[15]. This may be true for the general population as well.
Conclusion
The recent adoption of a nationwide infant HAV immuni-
zation policy in Israel has also been found to be both
medically and economically justifiable [16]. However,
this program is aimed at the infant population, for the
purpose of preventing early childhood infection. Screen-
ing the adult population in endemic countries like Israel
would enable seronegative adults to receive the
inactivated virus, thus preventing morbidity and mortality
resulting from infection. For the seropositive adult popu-
lation, unnecessary immunizations could be avoided.
Asking patients whether or not they need to be vaccinated
is, at best, unreliable, since most cases of HAV infection
occur in childhood and are asymptomatic, and even in
cases where jaundice is present the cause may not neces-
sarily be HAV. The health establishment in Israel needs to
investigate the benefits of routing testing for anti-HAV
serology, especially among the high-risk adult population
who were not actively immunized during childhood or
military service. Such routine testing is feasible, especially
in an era where it is accepted practice to conduct routine
screening tests for a number of preventive measures.
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